Sustained CD4 responses after virological failure of protease inhibitor-containing therapy

被引：0

作者：

Deeks, SG ^{[1
]}

Grant, RM

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] San Francisco Gen Hosp, San Francisco, CA 94110 USA

[3] Gladstone Inst Virol & Immunol, San Francisco, CA USA

来源：

ANTIVIRAL THERAPY | 1999年 / 4卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

This article explores current controversies related to 'discordant' responses to antiviral therapy, that is to say, patients with a sustained CD4 cell response despite virological failure. Observational clinical data of patients receiving protease inhibitor-based therapy who had a sustained CD4 cell count even with incomplete viral suppression will be presented, as well as possible mechanisms and clinical implications.

引用

页码：7 / 11

页数：5

共 50 条

[21] Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients
M Gyalrong-Steur
JR Bogner
U Seybold
European Journal of Medical Research, 16
[22] Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
Grabar, S
Pradier, C
Le Corfec, E
Lancar, R
Allavena, C
Bentata, M
Berlureau, P
Dupont, C
Fabbro-Peray, P
Poizot-Martin, I
Costagliola, D
AIDS, 2000, 14 (02) : 141 - 149
[23] High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy
Bélec, L
Piketty, C
Si-Mohamed, A
Goujon, C
Hallouin, MC
Cotigny, S
Weiss, L
Kazatchkine, MD
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05): : 1808 - 1812
[24] Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
Fatkenheuer, G
Theisen, A
Rockstroh, J
Grabow, T
Wicke, C
Becker, K
Wieland, U
Pfister, H
Reiser, M
Hegener, P
Franzen, C
Schwenk, A
Salzberger, B
AIDS, 1997, 11 (14) : F113 - F116
[25] Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy
Stone, SF
Price, P
French, MA
HIV MEDICINE, 2005, 6 (04) : 278 - 283
[26] Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens:: The APROVIR study
Masquelier, B
Peytavin, G
Leport, C
Droz, C
Duran, S
Verdon, R
Besnier, JM
Chêne, G
Raffi, F
Brun-Vézinet, F
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (10): : 1503 - 1507
[27] Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen
Valdez, H
Smith, KY
Landay, A
Connick, E
Kuritzkes, DR
Kessler, H
Fox, L
Spritzler, J
Roe, J
Lederman, MB
Lederman, HM
Evans, TG
Heath-Chiozzi, M
Lederman, MM
AIDS, 2000, 14 (01) : 11 - 21
[28] Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma
Tsutsumi, Yutaka
Ito, Shinichi
Ohigashi, Hiroyuki
Miyashita, Naohiro
Shimono, Joji
Shiratori, Souichi
Teshima, Takanori
LEUKEMIA & LYMPHOMA, 2015, 56 (11) : 3216 - 3218
[29] CHANGES IN LIPID PROFILES AFTER SWITCHING TO A PROTEASE INHIBITOR-CONTAINING cART - UNFAVOURABLE EFFECT OF FOSAMPRENAVIR IN OBESE PATIENTS
Gyalrong-Steur, M.
Bogner, J. R.
Seybold, U.
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2011, 16 (02) : 85 - 92
[30] Bach2 is required for sustained CD4 T cell responses
Sidwell, T.
Vasanthakumar, A.
Thelemann, C.
Kallies, A.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 102 - 103

← 1 2 3 4 5 →